These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11489241)

  • 41. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
    Knox KS; Adams JR; Djulbegovic B; Stinson TJ; Tomor C; Bennet CL
    Ann Oncol; 2000 Dec; 11(12):1591-5. PubMed ID: 11205468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
    Bero L; Oostvogel F; Bacchetti P; Lee K
    PLoS Med; 2007 Jun; 4(6):e184. PubMed ID: 17550302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review.
    Fabbri A; Lai A; Grundy Q; Bero LA
    Am J Public Health; 2018 Nov; 108(11):e9-e16. PubMed ID: 30252531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Financial relationships in economic analyses of targeted therapies in oncology.
    Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
    J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Industry funding and author-industry affiliation in clinical trials in psychiatry.
    Montgomery JH
    Am J Psychiatry; 2006 Jun; 163(6):1110-1; author reply 1111. PubMed ID: 16741218
    [No Abstract]   [Full Text] [Related]  

  • 46. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.
    Matcham J; Julious S; Pyke S; O'Kelly M; Todd S; Seldrup J; Day S
    Pharm Stat; 2011; 10(1):70-3. PubMed ID: 20187020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Funding, conflicts, and paradigms.
    Gelenberg AJ
    J Clin Psychiatry; 2005 May; 66(5):554. PubMed ID: 15889939
    [No Abstract]   [Full Text] [Related]  

  • 48. Why the Cochrane risk of bias tool should not include funding source as a standard item.
    Sterne JA
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):ED000076. PubMed ID: 24575440
    [No Abstract]   [Full Text] [Related]  

  • 49. Conflict of interest in the assessment of botulinum toxin A injections in patients with cerebral palsy: a systematic review.
    Sung KH; Chung CY; Lee KM; Lee YK; Lee SY; Lee J; Choi IH; Cho TJ; Yoo WJ; Park MS
    J Pediatr Orthop; 2013; 33(5):494-500. PubMed ID: 23752145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Food company sponsorship of nutrition research and professional activities: a conflict of interest?
    Nestle M
    Public Health Nutr; 2001 Oct; 4(5):1015-22. PubMed ID: 11784415
    [No Abstract]   [Full Text] [Related]  

  • 51. Minimizing bias in industry-sponsored outcomes research.
    Freeman RA
    Med Interface; 1994 Apr; 7(4):130-4. PubMed ID: 10133357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Managing financial conflicts of interest in research.
    Bero LA
    J Am Coll Dent; 2005; 72(2):4-9. PubMed ID: 16353375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study.
    Mintzes B; Swandari S; Fabbri A; Grundy Q; Moynihan R; Bero L
    BMJ Open; 2018 Feb; 8(2):e019027. PubMed ID: 29440213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmaceutical sales strategies and sponsorship.
    Sturgiss EA; Douglas K; Trumble SC
    Med J Aust; 2015 Feb; 202(3):131. PubMed ID: 25669470
    [No Abstract]   [Full Text] [Related]  

  • 55. Influence of drug company authorship and sponsorship on drug trial outcomes.
    Tungaraza T; Poole R
    Br J Psychiatry; 2007 Jul; 191():82-3. PubMed ID: 17602130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Getting it right: industry sponsorship and medical research.
    Baird P
    CMAJ; 2003 May; 168(10):1267-9. PubMed ID: 12743071
    [No Abstract]   [Full Text] [Related]  

  • 57. Bias from industry trial funding? A framework, a suggested approach, and a negative result.
    Barden J; Derry S; McQuay HJ; Moore AR
    Pain; 2006 Apr; 121(3):207-218. PubMed ID: 16495012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can a good tree bring forth evil fruit? The funding of medical research by industry.
    Capps B
    Br Med Bull; 2016 Jun; 118(1):5-15. PubMed ID: 27151955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sponsoring of research by the industry is not good for science].
    van Duppen D
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2283; author reply 2283. PubMed ID: 17076367
    [No Abstract]   [Full Text] [Related]  

  • 60. Conflict of interest and cost-effectiveness analysis.
    Krimsky S
    JAMA; 1999 Oct; 282(15):1474-5. PubMed ID: 10535440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.